Information Provided By: 
Fly News Breaks for October 3, 2018
SGEN
Oct 3, 2018 | 07:39 EDT
Barclays analyst Geoff Meacham raised his price target for Seattle Genetics to $95 saying this week's positive Adcetris E-2 data in frontline CD30-expressing peripheral T-cell lymphoma was another "win" for the company's core Adcetris franchise. The analyst thinks Adcetris is likely to capture his sixth indication and he keeps an Overweight rating on the shares. He we increased his Adcetris peak sales forecast by $550, representing 2022 product sales of $1.44B, above the consensus estimate of $1.31B.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
